Floatz logo

RELEBACTAM

Hematopoietic and Lymphoid Cell Neoplasm

M.D. Anderson Cancer CenterSmall moleculePhase 2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

116 Active assets in the Hematopoietic and Lymphoid Cell Neoplasm cohort.

Asset / SponsorPhaseRating
Fludarabine
National Cancer Institute (NCI)
Phase 3BB
FILGRASTIM
St. Jude Children's Research Hospital
Phase 2BB
Pegloticase
M.D. Anderson Cancer Center
Phase 4BB
Rasburicase
M.D. Anderson Cancer Center
Phase 4BB
HYDROMORPHON
M.D. Anderson Cancer Center
Phase 4BB

View all 50 →

Same molecule, other indications

RELEBACTAM is also rated in:

Critical IllnessDormant
CCC
Indicative ·
53 / 100
View asset →
bacterial pneumoniaDormant
CCC
Indicative ·
53 / 100
View asset →
cystic fibrosisDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →